Psychotropic medication-induced movement disorders among patients with mental illness on regular follow-up in northwest Ethiopia

Psychotropic medication-induced movement disorders represent an important clinical burden in psychiatric treatment. These adverse effects are associated with significant patient burden, including subjective distress, stigma, reduced medication adherence, and impaired quality of life, yet they remain under-recognized and frequently overlooked in routine clinical practice. They may occur with both first- and second-generation antipsychotics and other psychotropic medications. However, evidence on their prevalence and associated factors remains limited, particularly in low-resource settings. Therefore, this study aimed to determine the prevalence of psychotropic medication-induced movement disorders and their associated factors among patients receiving regular psychiatric follow-up care. An institution-based cross-sectional study was conducted from October 1 to November 30, 2025, among patients receiving regular psychiatric follow-up at the University of Gondar Hospital. Study participants were selected using a systematic random sampling technique. Psychotropic medication-induced movement disorders were assessed using the Extrapyramidal Symptom Rating Scale (ESRS). Data were analyzed using IBM SPSS Statistics version 27. Bivariable logistic regression analysis was initially performed, and variables with a p -value ≤ 0.25 were entered into the multivariable logistic regression model. Adjusted odds ratios (AORs) with 95% confidence intervals (CIs) were calculated, and statistical significance was declared at a two-sided p -value < 0.05. The prevalence of psychotropic medication-induced movement disorders was 38.6% (95% CI 33.7–43.5%). In the multivariable logistic regression analysis, being single (adjusted odds ratio [AOR] = 1.95; 95% CI 1.08–3.52), having a diagnosis of schizophrenia (AOR = 2.62; 95% CI 1.03–6.67), and an illness duration of more than 10 years (AOR = 3.65; 95% CI 1.05–12.70) were associated with higher odds of movement disorders. Compared with antidepressant use, first-generation antipsychotic use (AOR = 5.42; 95% CI 1.47–19.95) and second-generation antipsychotic use (AOR = 3.22; 95% CI 1.19–8.68) were also associated with higher odds of movement disorders. Psychotropic medication-induced movement disorders were common, affecting more than one-third of patients receiving regular psychiatric follow-up. Being single, having a diagnosis of schizophrenia, an illness duration of more than 10 years, and treatment with first- or second-generation antipsychotics were associated with higher odds of movement disorders. These findings underscore the importance of routine monitoring, early detection, and appropriate management of movement disorders in psychiatric care, particularly among patients with prolonged illness and those receiving antipsychotic treatment.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-14
DOI
https://doi.org/10.1038/s41598-026-78102-3
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Psychotropic medication-induced movement disorders among patients with mental illness on regular follow-up in northwest Ethiopia

Biruk Fanta, Birtukan Fasil, Mulu Getnet, Zemene Yiglet et al.
Scientific Reports
Schizophrenia research and treatment
article

Psychotropic medication-induced movement disorders among patients with mental illness on regular follow-up in northwest Ethiopia

Biruk Fanta, Birtukan Fasil, Mulu Getnet, Zemene Yiglet, Dawit Demelash, Mulualem Kelebie, Shegaye Shumet, Asnake Shitie
article en

Abstract

Psychotropic medication-induced movement disorders represent an important clinical burden in psychiatric treatment. These adverse effects are associated with significant patient burden, including subjective distress, stigma, reduced medication adherence, and impaired quality of life, yet they remain under-recognized and frequently overlooked in routine clinical practice. They may occur with both first- and second-generation antipsychotics and other psychotropic medications. However, evidence on their prevalence and associated factors remains limited, particularly in low-resource settings. Therefore, this study aimed to determine the prevalence of psychotropic medication-induced movement disorders and their associated factors among patients receiving regular psychiatric follow-up care. An institution-based cross-sectional study was conducted from October 1 to November 30, 2025, among patients receiving regular psychiatric follow-up at the University of Gondar Hospital. Study participants were selected using a systematic random sampling technique. Psychotropic medication-induced movement disorders were assessed using the Extrapyramidal Symptom Rating Scale (ESRS). Data were analyzed using IBM SPSS Statistics version 27. Bivariable logistic regression analysis was initially performed, and variables with a p -value ≤ 0.25 were entered into the multivariable logistic regression model. Adjusted odds ratios (AORs) with 95% confidence intervals (CIs) were calculated, and statistical significance was declared at a two-sided p -value < 0.05. The prevalence of psychotropic medication-induced movement disorders was 38.6% (95% CI 33.7–43.5%). In the multivariable logistic regression analysis, being single (adjusted odds ratio [AOR] = 1.95; 95% CI 1.08–3.52), having a diagnosis of schizophrenia (AOR = 2.62; 95% CI 1.03–6.67), and an illness duration of more than 10 years (AOR = 3.65; 95% CI 1.05–12.70) were associated with higher odds of movement disorders. Compared with antidepressant use, first-generation antipsychotic use (AOR = 5.42; 95% CI 1.47–19.95) and second-generation antipsychotic use (AOR = 3.22; 95% CI 1.19–8.68) were also associated with higher odds of movement disorders. Psychotropic medication-induced movement disorders were common, affecting more than one-third of patients receiving regular psychiatric follow-up. Being single, having a diagnosis of schizophrenia, an illness duration of more than 10 years, and treatment with first- or second-generation antipsychotics were associated with higher odds of movement disorders. These findings underscore the importance of routine monitoring, early detection, and appropriate management of movement disorders in psychiatric care, particularly among patients with prolonged illness and those receiving antipsychotic treatment.

Scientific Reports
UNSW Sydney (AU), Kirby Institute (AU), University of Gondar (ET)
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon